Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €99.28 EUR
Change Today +3.67 / 3.84%
Volume 2.7K
As of 7:44 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax:

Celgene Corporation, together with its subsidiaries, operates as an integrated global biopharmaceutical company. The company engages primarily in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The company engages in research in various scientific areas designed to deliver proprietary next-generation therapies, targeting areas, such as intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s primary commercial stage products include REVLIMID, ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside of the U.S.), OTEZLA, and ISTODAX. OTEZLA was approved by the U.S. Food and Drug Administration (FDA) in March 2014 for the treatment of adult patients with active psoriatic arthritis and in September 2014 for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In January 2015, OTEZLA was approved by the European Commission (EC) for the treatment of both psoriasis and psoriatic arthritis in certain adult patients. Commercial Stage Products REVLIMID (lenalidomide): REVLIMID is an oral immunomodulatory drug marketed in the United States and various international markets. REVLIMID continues to be evaluated in various clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma, myelodysplastic syndromes (MDS), mantle cell lymphoma, various lymphomas, and chronic lymphocytic leukemia. REVLIMID is distributed in the United States through contracted pharmacies under the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program, which is a proprietary risk-management distribution program tailored primarily to provide for the safe and appropriate distribution and use of REVLIMID. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of REVLIMID. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension): ABRAXANE is a solvent-free chemotherapy product, which is developed using the company’s proprietary nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. ABRAXANE is in various stages of investigation for breast cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC); and is under review by the European Medicines Agency for first-line treatment of NSCLC in adult patients who are not candidates for curative surgery. POMALYST/IMNOVID-(pomalidomide): POMALYST/IMNOVID is a small molecule that is administered orally and modulates the immune system and other biologically important targets. POMALYST/IMNOVID received its first approvals from the FDA and the EC during 2013 for the treatment of patients with multiple myeloma and relapsed and refractory multiple myeloma. POMALYST/IMNOVID is also being evaluated in multiple trials in various phases for expanded usage in multiple myeloma and in a phase II trial for systemic sclerosis. POMALYST is distributed in the United States through contracted pharmacies under the POMALYST REMS program, which is a proprietary risk-management distribution program tailored primarily to provide for the safe and appropriate distribution and use of POMALYST. Internationally, IMNOVID is distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the safe and appropriate distribution and use of IMNOVID. VIDAZA (azacitidine for injection): VIDAZA is a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and hi

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CG3:GR €99.28 EUR +3.67

CG3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $386.22 USD +12.29
Bristol-Myers Squibb Co $64.66 USD +0.93
Eli Lilly & Co $73.12 USD +1.25
Mylan NV $73.89 USD +1.63
Shire PLC 5,355 GBp +20.00
View Industry Companies
 

Industry Analysis

CG3

Industry Average

Valuation CG3 Industry Range
Price/Earnings 37.8x
Price/Sales 11.0x
Price/Book -- Not Meaningful
Price/Cash Flow 32.5x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.